The invention provides methods and agents that modulate RelA activity. These methods and modulators of RelA activity can be used to treat cancer progression of basal-like breast cancer, such as triple-negative breast cancer.

A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.

A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.

A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.

The present invention relates to a therapeutically active compound for the treatment of a medical condition, wherein the therapeutically active compound is administered in liquid formulation via the vagina by using an intravaginal ring. The present invention further relates to a therapeutically active compound selected from the group consisting of oxybutynin and other anti -muscarinic compounds, gonadotropin-releasing hormone (GnRH) and derivatives, both agonists and antagonists, nitroglycerin and other directly or indirectly acting cGMP enhancers, buprenorphine and other agonistic, antagonistic or partial (ant)agonistic opioids, nicotine and derivatives, lorazepam and other benzodiazepines, insulin and other blood glucose regulating compounds, FSH and other hormones for ovulation stimulation, pramipexol and other dopamine agonists, oxytocin and other hypothalamic peptides for the treatment of a medical condition, wherein the therapeutically active compound is administered in liquid formulation via the vagina by using an intravaginal ring.

The present invention relates to a therapeutically active compound for the treatment of a medical condition, wherein the therapeutically active compound is administered in liquid formulation via the vagina by using an intravaginal ring. The present invention further relates to a therapeutically active compound selected from the group consisting of oxybutynin and other anti -muscarinic compounds, gonadotropin-releasing hormone (GnRH) and derivatives, both agonists and antagonists, nitroglycerin and other directly or indirectly acting cGMP enhancers, buprenorphine and other agonistic, antagonistic or partial (ant)agonistic opioids, nicotine and derivatives, lorazepam and other benzodiazepines, insulin and other blood glucose regulating compounds, FSH and other hormones for ovulation stimulation, pramipexol and other dopamine agonists, oxytocin and other hypothalamic peptides for the treatment of a medical condition, wherein the therapeutically active compound is administered in liquid formulation via the vagina by using an intravaginal ring.

The present disclosure describes compositions comprising -lactam antibiotics and branched polyethylenimines (BPEI), having efficacy against various Gram-positive bacteria, for example Gram-positive bacteria having resistance against -lactam antibiotics, one non-limiting example of which is Methicillin-resistant Staphylococcus aureus (MRSA). The compositions result in the resensitization of such resistant bacterial strains to traditional antibiotic therapies such as -lactam antibiotics.

Methods are provided to prevent and to treat pressure ulcers (e.g., caused by ischemia) by using a vasodilator such as an angiotensin receptor blocker, ACE inhibitor, or calcium channel blocker. More particularly, the methods do not employ orally administered vasodilators, but instead vasodilators that are administered through contact with the epidermis, e.g., in topical or other form suitable for contact with tissues to be treated.

Methods are provided to prevent and to treat pressure ulcers (e.g., caused by ischemia) by using a vasodilator such as an angiotensin receptor blocker, ACE inhibitor, or calcium channel blocker. More particularly, the methods do not employ orally administered vasodilators, but instead vasodilators that are administered through contact with the epidermis, e.g., in topical or other form suitable for contact with tissues to be treated.

Please add the following heading and paragraph on a separate sheet, after the claims: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A.sub.2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A.sub.2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A.sub.2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.